






Active substances set

Search phrase: Hodgkin's disease

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Hodgkin's disease

Pembrolizumab	<p>Pembrolizumab as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.</p>	<p> NO REIMBURSEMENT</p> <p> ESMO</p>
Nivolumab	<p>Nivolumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.</p>	<p> REIMBURSEMENT WITH RESTRICTIONS</p> <p> ESMO</p>
Brentuximab vedotin	<p>Brentuximab Vedotin is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). Brentuximab Vedotin is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT). Brentuximab Vedotin is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following ASCT, or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.</p>	<p> REIMBURSEMENT WITH RESTRICTIONS</p> <p> ESMO</p>